Search

everythinglearnresearchcommunity

for

Search:↓

Cells from the lower part of hair follicles are a promising, less invasive option for immune system therapies.

Stem cells can be reprogrammed for various treatments, but safety and expansion challenges remain.

Newborn screening and gene therapy are expected to improve outcomes for Omenn syndrome patients.

Fetal skin has unique immune cells different from adult skin.

Hair follicle and adipose cell vesicles both protect neurons and reduce inflammation similarly.

Patients with RASopathies have a higher risk of autoimmune disorders and should be routinely screened.

A deficiency in the TTC7A gene causes immune problems, gut issues, and hair loss.

NKG2D+CD4+ T cells are higher in alopecia areata patients and may be involved in the disease.

Alopecia areata patients have fewer protective regulatory B cells, which may contribute to the disease.

ILC1-like cells can cause alopecia areata by attacking hair follicles.

Non-viral vectors show promise for safe and effective CRISPR/Cas9 gene editing in treating diseases.

Blood tests can help understand the genetic differences in people with alopecia areata, including how severe it is and if it's inherited.

The author now believes tricholemmal carcinoma is a rare type of infundibular squamous cell carcinoma and more research is needed on these tumors.

Mice treatments didn't grow hair, a patient treatment may affect immune response, and people with hair loss often feel anxious or depressed.

Repeated biopsies are crucial for managing lupus panniculitis when initial treatments fail.

The issue concluded that various skin conditions have different effective treatments and factors influencing them.

Type 3 Innate Lymphoid Cells help maintain skin health and balance, and are involved in skin diseases and healing.

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

Serum granulysin levels can indicate the activity and prognosis of alopecia areata.

Blocking TYK2 might be a new way to treat hair loss from alopecia areata.

The research identified unique metabolic activities in immune cells associated with hair loss in Alopecia Areata.

A man's skin condition was misdiagnosed and later identified as a rare type of skin cancer, which did not improve with treatment.

Leukemia can sometimes appear as unusual skin issues in children.

Alopecia areata may be treated by restoring hair follicle immune privilege and adjusting immune responses.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

UVB exposure in human skin causes macrophages to produce more IL-10 and less IL-12, leading to immunosuppression.

Alopecia areata is caused by immune attacks on hair follicles, affecting hair growth and quality of life.

Androgenetic alopecia involves immune cell disruptions, especially increased CD4+ T cells around hair follicles.

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.